Largest Phase 3 analysis of patients with Familial Hypercholesterolemia showed adding Praluent to standard-of-care therapy reduced LDL-cholesterol by an average 56 percent compared to standard-of-care alone(1)
Data from select familial hypercholesterolemia trials concurrently published in the European Heart Journal(2)
TARRYTOWN, NY, USA and PARIS, France I September 1, 2015 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in the ODYSSEY clinical trial program, Praluent® (alirocumab) significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C).1 This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo (p less than 0.0001) in both arms.1 Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.1
Results of this analysis were presented today at the ESC Congress 2015 in London, and the 78 week results from two of the four trials included in the analysis, ODYSSEY FH I and II, were concurrently published online in the European Heart Journal.
“Approximately 20 percent of HeFH patients achieve LDL-C less than 100 mg/dL with statins. In this analysis, up to 75 percent of patients who added Praluent to standard-of-care achieved their LDL-C goals by week 24,” said John J. P. Kastelein, M.D., Ph.D., FESC, Professor of Medicine, Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, the Netherlands. “Both Praluent 75 mg and 150 mg significantly reduced LDL-C levels below 100 mg/dL and sustained these lower levels through 78 weeks, offering patients and their doctors a flexible approach to treatment, with adverse events comparable to placebo.”
Across the pooled analysis, the most common adverse events (occurring in at least five percent of patients in any Praluent group) were nasopharyngitis, injection site reaction, influenza, headache, upper respiratory tract infection, arthralgia, back pain, urinary tract infection and myalgia.1
People with HeFH have an inherited form of high cholesterol and are unable to process the body’s natural supply of cholesterol in the liver, leading to very high levels of LDL-C that can block arteries (atherosclerosis) and can lead to a heart attack or stroke.3,4 If left untreated, people with HeFH typically have LDL-C levels of 200-400 milligrams/deciliter (mg/dL),5 are at high risk for premature atherosclerosis and cardiovascular (CV) events, and are at 20 times greater risk of developing heart disease.3,4
The analysis presented at ESC Congress 2015 evaluated the efficacy and safety of Praluent compared to placebo in 1,257 patients with HeFH. Data from four Phase 3 ODYSSEY trials, LONG TERM (HeFH patients only), HIGH FH, FH I, and FH II, were included in the analysis. In these trials, patients either received Praluent or placebo, in addition to standard-of-care, which included maximally-tolerated statins with or without other lipid-lowering therapies such as ezetimibe. In ODYSSEY LONG TERM and HIGH FH, patients were treated with Praluent 150 mg (n=348) every two weeks administered as a single 1-milliliter (mL) injection or placebo (n=174).1 In these patients, the average LDL-C at baseline was 168 mg/dL and 162 mg/dL in the Praluent and placebo groups respectively.1 In ODYSSEY FH I and FH II, patients were treated with Praluent 75 mg (n=490) every two weeks administered as a single 1-mL injection or placebo (n=245).1 In ODYSSEY FH I and FH II, patients had their dose adjusted to 150 mg at week 12 if they did not achieve their pre-specified LDL-C goal at week 8. In these patients, the average LDL-C level at baseline was 141 mg/dL in both the Praluent and placebo groups.1
Across all primary and secondary endpoints assessed, there were statistical differences in favor of Praluent compared to placebo.1 Patients treated with Praluent achieved average LDL-C levels of less than 85 mg/dL at week 12,6 and maintained reductions through 78 weeks of therapy.1
Summary of Primary and Select Secondary Endpoints
| |
Baseline
LDL-C |
% LDL-C
reduction
from
baseline
(week 24)a |
% achieved
LDL-C
goalb
(week 24) |
Greater % reduction for
Praluent vs. placebo groups
(on-treatment analysis)c |
| Week 24 |
Week 52 |
Week 78 |
Initially treated with 75 mg
(FH I and FH II) |
Praluent |
141 |
49d |
75d |
56d |
58d |
56d |
| Placebo |
141 |
-7 |
5 |
Initially treated with 150 mg
(LONG TERM and HIGH FH) |
Praluent |
168 |
55 |
64.5 |
57 |
60 |
63 |
| Placebo |
162 |
-1 |
4 |
Note: p less than 0.0001 vs. placebo for all data points
a Primary efficacy endpoint
b LDL-C goal either 70 mg/dL or 100 mg/dL depending on baseline CV risk
c On-treatment analysis (all other data is intention-to-treat)
d Includes 42 percent of patients treated with Praluent who had their dose adjusted to 150 mg at week 12
Praluent, a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), is approved for use in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic CV disease (ASCVD), who require additional lowering of LDL-C. The effect of Praluent on CV morbidity and mortality has not been determined. In July, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Praluent in certain adult patients with hypercholesterolemia, and a final decision from the European Commission is anticipated in September.
Important Safety Information for U.S.
Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT.
Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.
Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.
PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.
The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the “Instructions for Use” that comes with Praluent.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for the full Prescribing Information
References
- Kastelein JJP, Farnier M, Hovingh GK, et al. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1257 patients with heterozygous familial hypercholesterolaemia: analyses up to 78 weeks from four ODYSSEY trials. Oral presentation at ESC Congress 2015 (#5772): 29 August-2 September 2015.
- Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal 2015: doi:10.1093/eurheartj/ehv370.
- FH Foundation. What is FH? Available from: http://thefhfoundation.org/about-fh/what-is-fh/ Last accessed 6 August 2015.
- Goldberg AC, Hopkins PN, Toth PP et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011;5:S1–S8.
- Reiner Z, Catapano AL, De Backer G, et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2011: 32;1769–1818.
- Kastelein JJP, Farnier M, Hovingh GK, et al. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1257 patients with heterozygous familial hypercholesterolaemia: analyses up to 78 weeks from four ODYSSEY trials. Abstract from the ESC Congress 2015: 29 August-2 September 2015.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and have product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
SOURCE: Sanofi
Post Views: 228
Largest Phase 3 analysis of patients with Familial Hypercholesterolemia showed adding Praluent to standard-of-care therapy reduced LDL-cholesterol by an average 56 percent compared to standard-of-care alone(1)
Data from select familial hypercholesterolemia trials concurrently published in the European Heart Journal(2)
TARRYTOWN, NY, USA and PARIS, France I September 1, 2015 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in the ODYSSEY clinical trial program, Praluent® (alirocumab) significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C).1 This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo (p less than 0.0001) in both arms.1 Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.1
Results of this analysis were presented today at the ESC Congress 2015 in London, and the 78 week results from two of the four trials included in the analysis, ODYSSEY FH I and II, were concurrently published online in the European Heart Journal.
“Approximately 20 percent of HeFH patients achieve LDL-C less than 100 mg/dL with statins. In this analysis, up to 75 percent of patients who added Praluent to standard-of-care achieved their LDL-C goals by week 24,” said John J. P. Kastelein, M.D., Ph.D., FESC, Professor of Medicine, Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, the Netherlands. “Both Praluent 75 mg and 150 mg significantly reduced LDL-C levels below 100 mg/dL and sustained these lower levels through 78 weeks, offering patients and their doctors a flexible approach to treatment, with adverse events comparable to placebo.”
Across the pooled analysis, the most common adverse events (occurring in at least five percent of patients in any Praluent group) were nasopharyngitis, injection site reaction, influenza, headache, upper respiratory tract infection, arthralgia, back pain, urinary tract infection and myalgia.1
People with HeFH have an inherited form of high cholesterol and are unable to process the body’s natural supply of cholesterol in the liver, leading to very high levels of LDL-C that can block arteries (atherosclerosis) and can lead to a heart attack or stroke.3,4 If left untreated, people with HeFH typically have LDL-C levels of 200-400 milligrams/deciliter (mg/dL),5 are at high risk for premature atherosclerosis and cardiovascular (CV) events, and are at 20 times greater risk of developing heart disease.3,4
The analysis presented at ESC Congress 2015 evaluated the efficacy and safety of Praluent compared to placebo in 1,257 patients with HeFH. Data from four Phase 3 ODYSSEY trials, LONG TERM (HeFH patients only), HIGH FH, FH I, and FH II, were included in the analysis. In these trials, patients either received Praluent or placebo, in addition to standard-of-care, which included maximally-tolerated statins with or without other lipid-lowering therapies such as ezetimibe. In ODYSSEY LONG TERM and HIGH FH, patients were treated with Praluent 150 mg (n=348) every two weeks administered as a single 1-milliliter (mL) injection or placebo (n=174).1 In these patients, the average LDL-C at baseline was 168 mg/dL and 162 mg/dL in the Praluent and placebo groups respectively.1 In ODYSSEY FH I and FH II, patients were treated with Praluent 75 mg (n=490) every two weeks administered as a single 1-mL injection or placebo (n=245).1 In ODYSSEY FH I and FH II, patients had their dose adjusted to 150 mg at week 12 if they did not achieve their pre-specified LDL-C goal at week 8. In these patients, the average LDL-C level at baseline was 141 mg/dL in both the Praluent and placebo groups.1
Across all primary and secondary endpoints assessed, there were statistical differences in favor of Praluent compared to placebo.1 Patients treated with Praluent achieved average LDL-C levels of less than 85 mg/dL at week 12,6 and maintained reductions through 78 weeks of therapy.1
Summary of Primary and Select Secondary Endpoints
| |
Baseline
LDL-C |
% LDL-C
reduction
from
baseline
(week 24)a |
% achieved
LDL-C
goalb
(week 24) |
Greater % reduction for
Praluent vs. placebo groups
(on-treatment analysis)c |
| Week 24 |
Week 52 |
Week 78 |
Initially treated with 75 mg
(FH I and FH II) |
Praluent |
141 |
49d |
75d |
56d |
58d |
56d |
| Placebo |
141 |
-7 |
5 |
Initially treated with 150 mg
(LONG TERM and HIGH FH) |
Praluent |
168 |
55 |
64.5 |
57 |
60 |
63 |
| Placebo |
162 |
-1 |
4 |
Note: p less than 0.0001 vs. placebo for all data points
a Primary efficacy endpoint
b LDL-C goal either 70 mg/dL or 100 mg/dL depending on baseline CV risk
c On-treatment analysis (all other data is intention-to-treat)
d Includes 42 percent of patients treated with Praluent who had their dose adjusted to 150 mg at week 12
Praluent, a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), is approved for use in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic CV disease (ASCVD), who require additional lowering of LDL-C. The effect of Praluent on CV morbidity and mortality has not been determined. In July, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Praluent in certain adult patients with hypercholesterolemia, and a final decision from the European Commission is anticipated in September.
Important Safety Information for U.S.
Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT.
Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.
Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.
PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.
The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the “Instructions for Use” that comes with Praluent.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for the full Prescribing Information
References
- Kastelein JJP, Farnier M, Hovingh GK, et al. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1257 patients with heterozygous familial hypercholesterolaemia: analyses up to 78 weeks from four ODYSSEY trials. Oral presentation at ESC Congress 2015 (#5772): 29 August-2 September 2015.
- Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal 2015: doi:10.1093/eurheartj/ehv370.
- FH Foundation. What is FH? Available from: http://thefhfoundation.org/about-fh/what-is-fh/ Last accessed 6 August 2015.
- Goldberg AC, Hopkins PN, Toth PP et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011;5:S1–S8.
- Reiner Z, Catapano AL, De Backer G, et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2011: 32;1769–1818.
- Kastelein JJP, Farnier M, Hovingh GK, et al. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1257 patients with heterozygous familial hypercholesterolaemia: analyses up to 78 weeks from four ODYSSEY trials. Abstract from the ESC Congress 2015: 29 August-2 September 2015.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and have product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
SOURCE: Sanofi
Post Views: 228
